Lucid Diagnostics Inc. (LUCD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lucid Diagnostics Inc. (LUCD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.81

-0.01 (-0.86%)

At close: Jan 14, 2025, 3:59 PM

0.85

4.94%

After-hours Jan 14, 2025, 07:56 PM EST

undefined% (undefined)

Bid	0.79
Market Cap	48.01M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.12
PE Ratio (ttm)	-0.72
Forward PE	n/a
Analyst	Buy

Ask	0.85
Volume	111,938
Avg. Volume (20D)	477,355
Open	0.81
Previous Close	0.82
Day's Range	0.80 - 0.84
52-Week Range	0.63 - 1.58
Beta	undefined

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Oct 14, 2021

Employees 70

Stock Exchange NASDAQ

Ticker Symbol LUCD

Website https://www.luciddx.com

Analyst Forecast

According to 4 analyst ratings, the average rating for LUCD stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 208.99% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Lucid Diagnostics Inc. is scheduled to release its earnings on Mar 24, 2025, during market hours.
Analysts project revenue of $1.42M, reflecting a 36.54% YoY growth and earnings per share of -0.15, making a -34.78% decrease YoY.

Why Price Moved

2 months ago · Source

+5.95%

Lucid Diagnostics shares are trading higher after ... Unlock content with Pro Subscription

4 months ago · Source

-2.1%

Lucid Diagnostics shares are trading lower after the company announced the publication of its analytical validation study for the early detection of Esophageal cancer.

News

2 weeks ago · zacks.com

Lucid Inks New Partnership With VITALExam: Stock to Gain?

LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters.

2 months ago · seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Execut...